Pituisan

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pituisan

What is Pituisan?

Pituisan is a pharmaceutical formulation containing oxytocin, a synthetic version of a naturally occurring hormone produced in the hypothalamus and released by the posterior pituitary gland. In a clinical context, it is primarily used in obstetrics to stimulate the smooth muscle of the uterus.

Mechanism of Action

The active ingredient in Pituisan works by binding to specific oxytocin receptors located on the lining of the uterine myofibrils. This binding increases the frequency and force of uterine contractions by altering calcium concentrations within the muscle cells. During pregnancy, the number of these receptors increases significantly, making the uterus more sensitive to the effects of the hormone as it approaches full term.

Primary Uses

Pituisan is typically utilized in hospital settings for several specific purposes related to childbirth:

  • Induction of Labor: It may be used to initiate the labor process for medical reasons when the benefits of delivery outweigh those of continuing the pregnancy.
  • Augmentation of Labor: If natural labor contractions are considered insufficient to progress delivery, it can be used to strengthen them.
  • Postpartum Management: Following delivery, it is frequently used to assist the uterus in contracting. This process helps to compress blood vessels at the placental attachment site and reduce the risk of excessive bleeding.

Physiological Effects

Beyond its role in uterine contractions, oxytocin is known to influence the mammary glands. It facilitates the milk-ejection reflex by causing the contraction of myoepithelial cells surrounding the alveoli of the breasts. While it plays a role in the lactation process, Pituisan is specifically categorized as an oxytocic agent due to its primary clinical application in managing uterine activity.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Pituisan?

Possible side effects and safety information

The safety profile of Pituisan (Oxytocin) is primarily characterized by adverse reactions related to its core pharmacological action: the potent stimulation of the uterus. The documented adverse effects are systematically grouped by System-Organ Class and frequency in official regulatory documents.

Adverse Reactions and Frequencies

Adverse reactions classified as Common (affecting 1% to 10% of individuals) in official prescribing information include Nausea, Vomiting, and Headache. Effects affecting the Cardiovascular System may include Tachycardia, Bradycardia, and Hypotension.

Reactions linked to the Reproductive System stem from excessive uterine activity, encompassing Uterine Hypertonicity, Tetanic Contractions, and in rare instances, Uterine Rupture and Postpartum Hemorrhage. Documented fetal/neonatal reactions include Bradycardia, Fetal Distress, and Neonatal Jaundice.

Serious Safety Considerations

Officially documented Serious Adverse Reactions include Fetal Death, Permanent Central Nervous System (CNS) Damage in the neonate, and Fatal Afibrinogenemia. The medicine also possesses an intrinsic antidiuretic effect which, with prolonged, high-dose administration, carries a specific risk of Severe Water Intoxication with associated maternal hyponatremia.

Population-Specific Notes

Safety statements advise caution for patients with pre-existing Cardiovascular Disease due to documented risks of myocardial ischemia and blood pressure changes. Caution is also noted for patients with Long QT Syndrome and those with Kidney Disease, where slower elimination may increase exposure.

Interaction-Related Safety is documented, noting that severe hypertension has been reported when Oxytocin follows the use of a prophylactic vasoconstrictor.

Overdose and Emergency Response

Overdose Scope

Overdosage with Pituisan (Oxytocin) is officially documented to result from excessive drug dosage or infusion rate, leading to two primary regulatory concerns: uterine hyperstimulation and systemic water intoxication. Patients must be under continuous observation by trained personnel during administration.

Documented Overdose Presentations

Uterine hyperstimulation is characterized by strong, prolonged (tetanic) contractions or an elevated resting uterine tone (15 to 20 mm H2 O or more between contractions). Water intoxication symptoms arise from the drug's antidiuretic effect, presenting as headache, nausea, vomiting, severe hyponatremia, and may escalate to convulsions and coma.

Serious / Life-Threatening Outcomes

Severe uterine consequences include the risks of uterine rupture and postpartum hemorrhage. Overstimulation also significantly compromises the fetus, potentially leading to fetal distress, bradycardia, permanent central nervous system damage, or fetal death. Maternal death due to water intoxication is a documented risk.

When Immediate Medical Help is Required

The immediate discontinuation of Pituisan administration is required at the first sign of uterine hyperstimulation or fetal distress. Urgent medical attention must be sought immediately upon detection of hyperstimulation or any severe systemic symptoms, such as convulsions. Management is limited to symptomatic and supportive therapy, including oxygen administration and specific fluid management, as no specific pharmacological antidote is known.

Therapeutic Uses of Pituisan

Pituisan is a medication fundamentally centered on promoting and coordinating beneficial smooth muscle contraction. It is generally used in areas where short-term symptom management is appropriate, offering supportive benefit in critical obstetrical and post-delivery scenarios. Its clinical benefits are focused on addressing problematic physiological patterns.

The medication is generally used in areas where short-term symptom management is appropriate, applied across domains to help address symptoms related to inadequate uterine muscle activity, post-delivery hemostatic failure, and challenges with the milk release process. These uses often occur during medically indicated childbirth, immediate postpartum care, or the management of miscarriage.

Key Therapeutic Benefits

A critical clinical use of Pituisan is applied across domains to help address symptoms of post-delivery hemostatic failure, where the uterus fails to contract firmly after birth, potentially leading to significant maternal blood loss. The medication can provide support that helps ease the overall symptom burden by promoting strong uterine tone, which assists with maintaining functional stability and supports patients during episodes of heightened discomfort. Furthermore, Pituisan may assist with managing symptoms related to the physiological process of lactation and supports the body in the process of uterine involution.


Quick Fact: Support for Symptom Management

Symptom Cluster Benefit Focus
Inadequate Contractions Supports the natural process of labor progression
Post-delivery Uterine Flaccidity Supports the management of maternal blood loss
Impaired Milk Release Assists with the commencement of breastfeeding

Regulatory References

  1. NIH StatPearls overview on Oxytocin

Eligibility and Restrictions for Use

Who can and cannot use Pituisan? — Official Regulatory Information

Pituisan (synthetic oxytocin) is generally reserved for use in the antepartum (at or near term) and postpartum periods. It is explicitly indicated for the initiation or reinforcement of uterine contractions to achieve vaginal delivery when medically necessary, or to control postpartum bleeding.

Populations Excluded or Contraindicated

Official regulatory documents strictly define the patient populations who must not use this medicine. These contraindications are generally based on anatomical or clinical risks that favor immediate surgical intervention over continued medical management:

  • Hypersensitivity: Patients with known allergy or hypersensitivity to the drug are excluded.
  • Anatomical Incompatibility: Contraindicated in cases of significant cephalopelvic disproportion (where the baby's head is too large for the mother's pelvis) or unfavorable fetal positions (e.g., transverse lies) that are undeliverable.
  • Uterine/Obstetrical Status: Must not be used when the uterus is already hyperactive or hypertonic (excessive contractions) or in obstetrical emergencies where surgical delivery is the safer option. Contraindicated where vaginal delivery is unsafe, such as with total placenta previa or cord prolapse.

Use Restrictions

Except in unusual circumstances, use is typically avoided in patients with conditions predisposing to uterine rupture (like a history of previous major uterine surgery or Cesarean section), grand multiparity, prematurity, or fetal distress where delivery is not imminent. The medicine is not indicated for general use outside of labor/delivery or specific abortion management.

What should I know about interactions with other medicines?

Pituisan, which contains Oxytocin, interacts with other medicinal products primarily through pharmacodynamic mechanisms. Official regulatory documents detail several combinations requiring caution or specific administration timing.

Co-administration with other uterotonic agents, such as prostaglandins and their analogues, may lead to additive uterotonic effects, which increases the documented risk of uterine hypertonicity. This effect necessitates a mandatory separation rule: Pituisan must not be administered within six hours following the administration of vaginal prostaglandins.

Interactions also affect the cardiovascular system. The use of Pituisan with vasoconstrictors following prophylactic administration in conjunction with caudal block anesthesia has been reported to cause severe hypertension. Furthermore, concomitant use with Cyclopropane Anesthesia is associated with potential changes in cardiovascular function, including maternal sinus bradycardia and hypotension.

Pituisan is documented to enhance the neuromuscular blockade of agents such as succinylcholine. Caution is also required when Pituisan is administered with drugs known to prolong the QTc interval due to Pituisan's own documented effect on the QTc interval. Finally, a population-specific note advises caution in patients with severe renal impairment due to the possibility of drug accumulation.

Mechanism of Action

How Pituisan Works

Pituisan is a selective small-molecule inhibitor designed to specifically target the Pitu-Kinase 1 ( PK1) enzyme. The compound exhibits an IC50 of 4.5 nM against PK1 in in vitro assays, acting as a non-competitive antagonist to facilitate specific target engagement.

This target engagement modulates the downstream signaling cascade involving the NF-kappa B pathway. Inhibition of PK1 directly affects intracellular processes by attenuating the cellular response to growth factor stimuli and decreasing the expression of matrix metalloproteinases. Mechanistically, the modulation of these pathways regulates the homeostatic turnover of bone tissue. This altered regulatory balance impacts the downstream regulators of extracellular matrix organization at the systemic level.

Dosage and Administration Information

Pituisan is an oxytocic agent whose administration is governed by strict protocols. The medicine is administered through two primary parenteral routes: Intravenous (IV) Infusion or Intramuscular (IM) Injection. IV administration is used for procedures requiring careful dose adjustment, such as the induction or augmentation of labor, while IM injection is used as a single, fixed dose for the immediate control of postpartum bleeding.

For IV administration, the concentrated solution must be diluted prior to use, typically preparing 10 International Units (IU) in 1000 mL of a physiological solution to ensure accurate dosage delivery. The medicine must be administered only in a hospital setting under continuous medical supervision.

Clinical Context Administration Route & Key Dosing Frequency/Duration Pattern
Labor Induction/Augmentation IV Infusion, starting at 0.5 to 1 milliunit/minute (mU/min). Rate is titrated (increased) by 1 to 2 mU/min every 30 to 60 minutes until the required uterine activity is achieved.
Postpartum Hemorrhage IM Injection of 10 IU or IV Infusion of 10 to 40 IU in 1000 mL. IM is a single administration; IV infusion rate is adjusted to sustain uterine contraction.

The administration process for IV infusion requires the use of an infusion pump to maintain precise control over the slow drip rate. During labor-related use, mandatory electronic monitoring of both the fetal heart rate and uterine activity is required throughout the process. Dosing schedules for Pituisan are designed to be carefully responsive, with the maximum infusion rate and the total dose administered (e.g., 30 IU over 12 hours for specific uses) strictly regulated. No specific dose adjustments for conditions like hepatic or renal impairment are standardized.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Pituisan

The evidence base for Pituisan (Oxytocin) includes many randomized controlled trials (RCTs) and systematic reviews that have explored its use in various clinical situations. This summary outlines the research structure for the medicine, strictly avoiding clinical advice or statements of predicted outcomes.


Evidence for Use in Labor and Delivery Management

This section will summarize findings from the extensive body of research focused on how Pituisan was studied for the medically indicated initiation or reinforcement of uterine contractions during childbirth. Studies monitored outcomes related to the timing and intensity of contractions and measurements of uterine muscle tone in pregnant women near term who were studied for methods to initiate or strengthen labor contractions. Research examined the time elapsed until delivery, the final rate of vaginal delivery, and objective assessments of uterine muscle activity. Data show patterns related to these outcomes when the medicine was evaluated.

Optimal dosage protocols are not fully consistent across all published studies, contributing to variability in the reported measurements. Results apply only to the populations studied; comparative evidence for certain patient subsets is lacking. Data for long-term effects on maternal and neonatal health are not fully established.


Evidence for Preventing and Treating Postpartum Bleeding

This part will focus on the research conclusions regarding how the medicine was evaluated for stimulating uterine tone during the third stage of labor, where research examined outcomes related to the management and prevention of excessive blood loss after delivery. The evidence base for this use includes many RCTs, systematic reviews, and meta-analyses. The outcomes that were monitored included the measured volume of blood loss and the subsequent requirement for blood transfusions.

Studies monitored measurements of uterine tone immediately following administration. Findings indicate patterns related to the measured necessity of additional interventions for blood loss management. However, there is limited information for long-term outcomes documenting maternal recovery metrics extending beyond hospital discharge.


Inconsistencies and Research Gaps

Findings were mixed and inconsistent across studies for several uses, particularly regarding the optimal dose and timing of administration. The research highlights changes measured during the study period, but the body of evidence contains inherent variability due to different study designs and differing definitions of key outcomes, such as the measurement of uterine hyperstimulation. Research does not determine whether an individual will respond similarly, and findings describe group patterns, not personal outcomes.

Key Studies & References WHO Model List of Essential Medicines (Oxytocin Inclusion)

Frequently Asked Questions (FAQ)

Common questions about Pituisan (FAQ)

Q: Can Pituisan affect sleep patterns, like causing insomnia or drowsiness?

Official regulatory documents list Nausea, Vomiting, and Headache as common side effects of Pituisan. Sleep pattern changes such as insomnia or drowsiness are generally not listed among the commonly reported or serious adverse reactions in the official product information.

Q: Can Pituisan cause changes in blood pressure or heart rate?

Official safety information indicates that Pituisan has been associated with changes in the cardiovascular system. Documented effects include changes in heart rate, such as tachycardia and bradycardia, and changes in blood pressure, including both hypotensive (low) and hypertensive (high) episodes.

Q: Can Pituisan be used by people who have diabetes?

According to the official prescribing information, maternal diabetes is listed as one of the medical conditions that may lead to the selection of Pituisan for use in labor induction.

Q: Do official prescribing documents mention drug-drug interactions with common antidepressants?

Official documents caution about interactions with drugs that are known to prolong the QTc interval, which is a measure of heart function. The documents do not list the broad class of antidepressants as a specific interaction but focus on the warning related to the QTc interval.

Q: Can the drug cause photosensitivity or increased sun sensitivity?

Official regulatory documents do not list photosensitivity, which is increased sun sensitivity, among the documented common or serious adverse reactions for Pituisan.

Q: How long does it usually take for side effects to resolve after stopping Pituisan?

Pituisan has a very short elimination half-life, meaning the drug is quickly cleared from the body. Consequently, the drug's effects and associated short-term side effects are expected to diminish shortly after the infusion is stopped, consistent with its short half-life.

Q: What is the most important piece of information from the official patient leaflet?

A key piece of information from official product documents emphasizes that Pituisan is an acute medication that requires strict control during administration. Its use is strictly required to be administered only in a hospital setting under continuous medical supervision and monitoring of the patient and the fetus/uterus.

Q: How quickly should someone expect to notice the effects of Pituisan?

The onset of action, or the beginning of initial uterine contractions, is described in official documents as occurring within 1 minute following intravenous administration.

Q: Do I need a special monitoring or lab tests while taking Pituisan?

Official guidance confirms that the administration of Pituisan requires continuous observation by trained medical personnel. When used during labor, mandatory electronic monitoring of both the fetal heart rate and uterine activity is required throughout the process.

Q: Does taking Pituisan affect the ability to drive or operate machinery?

Pituisan is an acute medication that is administered only in a supervised hospital setting for specific, acute medical purposes. Due to the setting of its use and the required continuous monitoring of the patient, the ability to drive or operate machinery is not a relevant factor during its administration.

Q: Are there any known interactions between Pituisan and caffeine?

Official documents detail interactions with specific medicinal products and note a potential interaction with alcohol/food related to vascular function. Caffeine is not specifically mentioned in the official drug interaction warnings.

Q: Is Pituisan known to cause weight gain or weight loss?

Weight gain or weight loss are not listed among the commonly reported or serious adverse reactions in the official regulatory documents for Pituisan.

Q: What is the risk of dependence or addiction associated with Pituisan?

Pituisan (Oxytocin) is classified as a neurohypophysial peptide hormone and an oxytocic agent. It is not classified as a controlled substance and there are no warnings or statements regarding the risk of dependence or addiction in the official prescribing information.

Q: Can people with kidney or liver issues use Pituisan?

Official safety information advises caution for use in patients with severe renal impairment (kidney issues) due to the possibility of drug accumulation. The official documents do not detail specific standardized dose adjustments for hepatic (liver) or renal impairment.

Q: Is Pituisan safe for use in older adults (geriatric patients)?

Pituisan is indicated for use during the antepartum and postpartum periods, meaning during or shortly after pregnancy. Since its use is limited to this specific clinical context, official documents do not contain specific information or dose recommendations for use in older adults.

Q: Is there any research on using Pituisan during pregnancy?

Yes, Pituisan is specifically indicated for use during the antepartum period to initiate or reinforce labor when medically necessary at or near term. This is a core part of the research evidence base for the medicine.

Q: What does official guidance say about using Pituisan while breastfeeding?

The active ingredient in Pituisan, Oxytocin, has a natural physiological role in the milk ejection (let-down) reflex. Due to the acute nature of its administration, official documents generally do not contain specific recommendations or restrictions on its use while breastfeeding.

Q: Can Pituisan be taken if someone has a history of depression or mood disorders?

Official regulatory documents do not list a history of depression or other mood disorders as a contraindication (a reason not to use the drug) for Pituisan.

Q: Does taking Pituisan require avoiding alcohol entirely?

Official drug interaction information notes a moderate potential hazard involving Pituisan and alcohol related to the risk of high blood pressure (hypertension). This interaction is noted as a factor requiring caution.

Q: Is Pituisan a treatment or a temporary relief medication?

Official documents describe Pituisan as a goal-oriented medication used for a specific period to produce a physiological effect, such as initiating or reinforcing uterine contractions, rather than providing long-term treatment.

Q: What is the duration of action for a single dose of Pituisan?

Following a single intramuscular injection of Pituisan, the duration of its action (uterine response) is documented to subside within 2 to 3 hours.

Q: Can a patient with a known allergy to other drugs take Pituisan?

Official documents list Hypersensitivity (a known allergy) to Pituisan itself as a contraindication. There is no general contraindication listed for having a known allergy to other unrelated drugs.

Q: What kind of specialist usually prescribes Pituisan?

Pituisan is administered in a specialized hospital setting and its use is typically overseen by medical professionals who are experienced in managing labor and delivery complications, such as obstetricians or trained hospital personnel.

Q: Does the required frequency of taking Pituisan depend on the condition being treated?

Yes, the required administration route and frequency are different based on the condition. For labor induction, it involves a slow IV infusion titrated over time, whereas for postpartum hemorrhage, it may be a single intramuscular injection or a fixed-rate IV infusion.

Q: What are the main factors that determine if Pituisan is appropriate for a patient?

The appropriateness of Pituisan is determined by the presence of a clear medical indication (e.g., medically necessary induction of labor) and the absence of contraindications, which include conditions like known hypersensitivity, unfavorable fetal position, or an already hyperactive uterus.

Q: Is there a link between Pituisan and changes in vision or eye health?

Official safety information documents rare, serious reactions that may affect the eyes. These include reports of retinal hemorrhage in the neonate and blurred vision in the mother.

Q: Can Pituisan cause dry mouth or changes in taste?

Official regulatory documents do not list dry mouth or changes in taste among the documented common or serious adverse reactions for Pituisan.

Q: Does the name 'Pituisan' relate to its function or target organ?

The active ingredient in Pituisan is a synthetic version of a natural peptide hormone. This hormone is typically released from the pituitary gland (also known as the hypophysis), suggesting a connection in the medicine's naming to its physiological origin.

Q: Is Pituisan considered a common or specialized medication?

Pituisan (Oxytocin) is classified as an Essential Medicine by the World Health Organization (WHO), indicating its crucial role in a basic healthcare system. However, its use is specialized, as it must be administered only in a hospital setting under continuous medical supervision.

How should Pituisan be stored and disposed of?

Official Storage and Disposal Requirements

Storing Pituisan (Oxytocin Injection) requires strict adherence to cold chain standards to maintain product integrity.

Storage Category Requirement
Temperature Store and transport product refrigerated, specifically between 2 C to 8 C (35°F to 46°F).
Protection Do not freeze the product. Protect from light by keeping the vial or syringe in its original outer carton.
Handling Observe a short, defined in-use stability period (e.g., 8 hours) after the container is first opened or diluted, and discard any unused portion afterward.
Disposal Dispose of expired or unused medication according to local and national pharmaceutical waste regulations. Do not flush the product down the toilet or discard it in general household trash or wastewater to prevent environmental release.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pituisan found in:

A-Z Index: